Determination of Nasopharyngeal Carriage of Streptococcus pneumoniae and Response to the Pneumococcal Polysaccharide Vaccine in Children with Recurrent Infections

2021 ◽  
pp. 128-137
Author(s):  
Intty Leiva ◽  
Jaime Inostroza ◽  
Arnoldo Quezada
Keyword(s):  
Streptococcus Pneumoniae ◽  
Polysaccharide Vaccine ◽  
Pneumococcal Polysaccharide Vaccine ◽  
Nasopharyngeal Carriage ◽  
Recurrent Infections

Pneumococcal vaccine in adults reduces the risk of infections caused by Streptococcus pneumoniae

2016 ◽  
Vol 94 (1) ◽  
pp. 61-66
Author(s):  
Yulia G. Belocerkovskaja ◽  
A. G. Romanovskih ◽  
E. A. Styrt
Keyword(s):  
Streptococcus Pneumoniae ◽  
Conjugate Vaccine ◽  
Pneumococcal Vaccine ◽  
Pneumococcal Conjugate Vaccine ◽  
Risk Group ◽  
Severe Disease ◽  
Polysaccharide Vaccine ◽  
Pneumococcal Vaccines ◽  
Pneumococcal Polysaccharide Vaccine ◽  
Pneumococcal Infections

Streptococcus pneumoniae is a major cause of severe disease worldwide, particularly in the risk population. Two pneumococcal vaccines are currently available for specific prevention of pneumococcal infections among adults in Russia: a 23-valent pneumococcal polysaccharide vaccine (PPSV23) and a 13-valent pneumococcal conjugate vaccine (PCV13). The article describes modern views on the effectiveness and safety of two pneumococcal vaccines in adults with underlying medical conditions and adults aged ≥65 years and provides current recommendations for routine use of PPSV23 and PCV13 among persons included in the risk group.

scholarly journals Pneumococcal Nasopharyngeal Carriage in Infants of Mothers Immunized with 23V Non-conjugate Pneumococcal Polysaccharide Vaccine

2012 ◽  
Vol 58 (5) ◽  
pp. 348-352 ◽  
Author(s):  
C. C. Lopes ◽  
E. N. Berezin ◽  
D. Scheffer ◽  
R. Huziwara ◽  
M. I. Sliva ◽  
...  
Keyword(s):  
Polysaccharide Vaccine ◽  
Pneumococcal Polysaccharide Vaccine ◽  
Nasopharyngeal Carriage

scholarly journals Effectiveness of 23-Valent Pneumococcal Polysaccharide Vaccine Against Pneumococcal Diseases Among the Elderly Aged 60 Years or Older: A Matched Test Negative Case-Control Study in Shanghai, China

2021 ◽  
Vol 9 ◽  
Author(s):  
Xiaodong Sun ◽  
Xiang Guo ◽  
Jing Qiu ◽  
Genming Zhao ◽  
Xinxin Xu ◽  
...  
Keyword(s):  
Streptococcus Pneumoniae ◽  
Pneumococcal Disease ◽  
Case Control Study ◽  
The Elderly ◽  
Case Control ◽  
Polysaccharide Vaccine ◽  
Pneumococcal Polysaccharide Vaccine ◽  
Negative Case ◽  
Multiple Variables ◽  
Control Study

Background:Streptococcus pneumoniae infection among adults, especially in adults over 60 years old in China results in a large number of hospitalizations and a substantial financial burden. This study assessed the vaccine effectiveness (VE) of 23-valent pneumococcal polysaccharide vaccine (PPV23) against pneumococcal diseases among the elderly aged 60 years or older in Shanghai, China.Methods: We conducted a test-negative case–control study among the elderly aged 60 years or older who sought care at hospitals in 13 districts of Shanghai from September 14, 2013 to August 31, 2019. A case was defined as pneumococcal disease and testing positive for Streptococcus pneumoniae. Controls had symptoms congruent with pneumococcal disease but were negative for Streptococcus pneumoniae. We conducted 1:2 matching by gender, age, hospital and admission date. Vaccination status was verified from the immunization system database. VE was calculated with conditional logistic regression according to the formula (1–OR) ×100%.Results: Overall, 603 adults aged 60 years or older with pneumococcal disease and positive for Streptococcus pneumoniae were included as cases, and 19.6% (118 persons) had a recorded PPV23 vaccination. The controls included 1,206 adults, whose vaccination rate was 23.8% (287 persons). The VE against pneumococcal diseases among the whole population was 24% (95% CI: 2%, 40%) and among women 44% (95% CI: 6%, 67%). After adjusting for multiple variables, the effectiveness of PPV23 against pneumococcal diseases was still statistically significant with VE for all of 25% (95% CI: 3%, 42%) and VE for women of 49% (95% CI: 11%, 71%).Conclusion: PPV23 was effective against pneumococcal diseases in adults aged 60 years or older in Shanghai, China. Its relatively high effectiveness among women warrants this group to be particularly targeted for vaccination, with further research on why vaccination effectiveness is less among men.

scholarly journals Adult invasive pneumococcal disease pre- and peri-pneumococcal conjugate vaccine introduction in a tertiary hospital in Singapore

2009 ◽  
Vol 58 (1) ◽  
pp. 101-104 ◽  
Author(s):  
Li-Yang Hsu ◽  
See Weng Lui ◽  
Jia Ling Lee ◽  
Hazwany Md Mahrom Hedzlyn ◽  
Debra Han-Lin Kong ◽  
...  
Keyword(s):  
Streptococcus Pneumoniae ◽  
Pneumococcal Disease ◽  
Tertiary Hospital ◽  
Invasive Disease ◽  
Polysaccharide Vaccine ◽  
Attributable Mortality ◽  
Study Cohort ◽  
Pneumococcal Polysaccharide Vaccine ◽  
Vaccine Introduction ◽  
The Us

Streptococcus pneumoniae isolates causing invasive disease at a large tertiary institute in Singapore from 2000 to 2007 were serotyped, with 84 (43.8 %) and 159 (82.8 %) isolates belonging to serotypes covered by the pneumococcal heptavalent conjugate and polysaccharide vaccines, respectively. All non-meningitis isolates were susceptible to penicillin, and the attributable mortality was 21.4 %. Patients who fulfilled the US Advisory Committee on Immunization Practices criteria for vaccination with the pneumococcal polysaccharide vaccine comprised 74.0 % of the study cohort and had a significantly higher mortality risk.

Sign in / Sign up

Export Citation Format

Share Document